345 results on '"Egeberg, Alexander"'
Search Results
2. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
3. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
4. Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
5. Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials
6. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
7. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
8. Adult patients with alopecia areata report a significantly better medication adherence compared to those with atopic dermatitis: Results from a large cross-sectional cohort study
9. Biomarkers of systemic inflammation are associated with disease severity and metabolic syndrome in patients with hidradenitis suppurativa
10. No associations between type 1 diabetes and atopic dermatitis, allergic rhinitis, or asthma in childhood: a nationwide Danish case-cohort study
11. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial
12. Development and internal validation of a diagnostic prediction model for psoriasis severity
13. A fragment of type VI collagen alpha-6 chain is elevated in serum from patients with atopic dermatitis, psoriasis, hidradenitis suppurativa, systemic lupus erythematosus and melanoma
14. Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort
15. Use of methotrexate and risk of skin cancer: a nationwide case–control study
16. Reduced Skin Microbiome Diversity in Infancy Is Associated with Increased Risk of Atopic Dermatitis in High-Risk Children
17. Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in Denmark
18. Incidence and geographic differences in keratinocyte carcinoma and Bowen's disease in office‐based dermatological practice between 2013 and 2022: A nationwide Danish registry‐based study.
19. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis
20. Fatigue is associated with disease severity in adult patients with hidradenitis suppurativa
21. Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study
22. Estimating the burden of skin diseases using patient‐reported daily time trade‐off as a measure of disease impact and unmet needs
23. Infusion of Pituitary Adenylate Cyclase–Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan
24. Awareness and Expectations Surrounding Family Planning and Pregnancy Among Danish Patients with Chronic Inflammatory Disease of the Skin or Joints: Results from an Online Survey
25. Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral
26. Risk of skin cancer in patients with vitiligo in Denmark: A nationwide cohort study
27. Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study
28. A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents
29. Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib
30. Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks
31. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark
32. Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
33. Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis—A Nationwide 20-Year Cohort Study
34. Prevalence and incidence of patients with generalized pustular psoriasis in Denmark—A nationwide registry‐based study
35. Disease‐ and treatment‐related expectations, attitudes, and beliefs among adult patients initiating or switching biological therapies for psoriasis
36. Psychiatric co‐morbidity in patients with hidradenitis suppurativa: A cross‐sectional study of clinical characteristics and burden of disease
37. Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study
38. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: A Danish population-based cohort study
39. Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study
40. Increased Suicide Risk in Patients with Hidradenitis Suppurativa
41. Mild-to-moderate severity of psoriasis may be assessed remotely based on photographs and self-reported extent of skin involvement
42. Prognostic implications of high-sensitivity cardiac troponin in patients with suspected myocardial infarction with or without psoriasis
43. Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment – a nationwide cohort study
44. Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)
45. Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis Suppurativa
46. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort
47. Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years
48. Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program
49. Trajectories For Scalp Hair Regrowth In Patients With Severe Alopecia Areata Treated With Baricitinib
50. Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.